SCHEMBL7229249

SCHEMBL7229249

Cc1cccc(O)c1NC(=O)OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.65
RAB9A P51151 1/20 0.65
MAOA P21397 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.54
CASP3 P42574 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
LMNA P02545 1/20 0.53
MGLL Q99685 1/20 0.51
NLRP3 Q96P20 2/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929631 0.84 NPC1 (0.63) NPC1RAB9AMAOASMN1; SMN2CASP3
SCHEMBL28564954 0.82 NPC1 (0.64) NPC1RAB9AMAOASMN1; SMN2CASP3
SCHEMBL29956120 0.82 NPC1 (0.60) NPC1RAB9AMAOASMN1; SMN2CASP3
SCHEMBL3041603 0.81 NPC1 (0.58) NPC1RAB9AMAOASMN1; SMN2CASP3
SCHEMBL5213739 0.79 NPC1 (0.60) NPC1RAB9AMAOASMN1; SMN2L3MBTL1
SCHEMBL5853278 0.79 NPC1 (1.00) NPC1RAB9ASMN1; SMN2CASP3L3MBTL1
SCHEMBL5220382 0.78 NPC1 (0.58) NPC1RAB9AMAOASMN1; SMN2L3MBTL1
SCHEMBL4912455 0.78 NPC1 (0.52) NPC1RAB9AMAOASMN1; SMN2CASP3
SCHEMBL30522295 0.77 NPC1 (0.69) NPC1RAB9ASMN1; SMN2CASP3LMNA
SCHEMBL16193532 0.77 NPC1 (0.69) NPC1RAB9ASMN1; SMN2CASP3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514997-B2 Block the activity of picornaviral 3C protease AGOURON PHARMACEUTICALS, INC. 2003-02-04 US disclosed
EP-1252145-A1 ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20010047006-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. 2001-11-29 US disclosed
WO-2001040189-A1 ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047006-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis RNASE1, SERPINB1, RNASEH1 NPC1 420/4885RAB9A 2911/4885MAOA 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.